BNTX - Vaxart: Practical COVID-19 Oral Pill For 2021
- Vaxart as a COVID-19 vaccine play had surged after upbeat news in June, but is now at lower valuations.
- Still, the stock price is on a net one-year uptrend, as a result of the biotech's quite unique treatment being developed against the coronavirus.
- Moreover, the company's image has been somewhat tainted by the court case over the timing of warrants.
- Vaxart's platform, which uses the Non-Replicating Viral Vector, is based on the same approach as for the Oxford-AstraZeneca vaccine.
- Finally, both financial capacity and diversification strengths are there.
For further details see:
Vaxart: Practical COVID-19 Oral Pill For 2021